IFF Q2 reported EPS rose to $2.38 from $0.66 as sales fell 4%; $500M buyback approved
IFF reported second-quarter 2025 net sales of $2.76 billion, down 4% from a year earlier, while reported diluted EPS was $2.38 versus $0.66 a year earlier. The company reaffirmed its full-year 2025 guidance, authorized a $500 million share repurchase program with no set end date, and agreed to sell its soy crush, concentrates and lecithin business to Bunge, which the company said generated about $240 million in 2024 revenue. For shareholders, first-half results include a $1,153 million goodwill impairment that produced a $405 million net loss for the six months.
Key points
- Q2 net sales $2.76 billion, down 4% reported; up 3% on a comparable currency-neutral basis
- Q2 reported diluted EPS $2.38 versus $0.66 a year earlier; first-half EPS was a loss of $1.59
- Board authorized up to $500 million in share repurchases with no specified term or termination date
- Full-year 2025 guidance reaffirmed: sales of $10.6 billion to $10.9 billion and adjusted operating EBITDA of $2 billion to $2.15 billion
The filing
Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.